retatrutide triple agonist obesity trial 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Medscape | Retatrutide, Eli Lilly's

With tools like 1:1 health coaching, monthly provider check-ins, and free insurance navigation, Ro makes evidence-based weight loss more approachable and sustainable for people who qualify

For example, if you inject into the left side of your abdomen one week, move to the right side or your thigh the following week

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

There are no clinical trials on this patch format, no data testing this ingredient combo, and no human studies showing increased GLP-1 levels from this approach

doi: 10.1016/j.molmet.2013.12.001

This price tag often forces patients to choose between their health goals and their financial stability, a decision nobody should have to make